Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-16 4:58 pm Purchase | 2020-12-31 | 13G | Madrigal Pharmaceuticals, Inc. MDGL | Baker Bros. Advisors LP | 1,499,213 9.700% | 329,935 (+28.22%) | Filing History |
| 2021-02-16 4:58 pm Purchase | 2021-02-16 | 13G | Immunocore Holdings plc IMCR | Baker Bros. Advisors LP | 3,352,357 7.500% | 3,352,357 (New Position) | Filing History |
| 2021-02-16 4:53 pm Purchase | 2020-12-31 | 13G | Mereo BioPharma Group plc MREO | Baker Bros. Advisors LP | 39,631,929 11.400% | 39,631,929 (New Position) | Filing History |
| 2021-02-16 4:53 pm Purchase | 2020-12-31 | 13G | Amarin Corporation plc AMRN | Baker Bros. Advisors LP | 1,405,757 7.200% | 272,281 (+24.02%) | Filing History |
| 2021-02-16 4:53 pm Purchase | 2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Baker Bros. Advisors LP | 195,701 9.900% | 127,157 (+185.51%) | Filing History |
| 2021-02-16 4:53 pm Purchase | 2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | Baker Bros. Advisors LP | 18,178,881 9.990% | 2,303,756 (+14.51%) | Filing History |
| 2021-02-16 4:50 pm Sale | 2020-12-31 | 13G | InflaRx N.V. IFRX | Baker Bros. Advisors LP | 856,228 3.000% | -922,187 (-51.85%) | Filing History |
| 2021-02-16 4:40 pm Purchase | 2020-12-31 | 13G | OPTHEA LTD SPONSORED ADR OPTEY | Baker Bros. Advisors LP | 33,963,240 9.800% | 33,963,240 (New Position) | Filing History |
| 2021-02-16 4:35 pm Purchase | 2020-12-31 | 13G | Cerus Corporation CERS | Baker Bros. Advisors LP | 13,733,059 8.200% | 2,963,258 (+27.51%) | Filing History |
| 2021-02-16 4:27 pm Sale | 2020-12-31 | 13G | Krystal Biotech, Inc. KRYS | Baker Bros. Advisors LP | 698,874 3.500% | -335,800 (-32.45%) | Filing History |
| 2021-02-16 4:22 pm Purchase | 2020-12-31 | 13G | Altimmune, Inc. ALT | Baker Bros. Advisors LP | 1,884,451 5.100% | 1,884,451 (New Position) | Filing History |
| 2021-02-16 4:16 pm Purchase | 2020-12-31 | 13G | Verastem, Inc. VSTM | Baker Bros. Advisors LP | 845,337 6.000% | 845,337 (New Position) | Filing History |
| 2021-02-16 4:08 pm Purchase | 2020-12-31 | 13G | Adaptimmune Therapeutics plc ADAPY | Baker Bros. Advisors LP | 58,985,262 6.400% | 58,985,262 (New Position) | Filing History |
| 2021-02-05 4:53 pm Unchanged | 2021-02-05 | 13G | Zymeworks Inc. ZYME | Baker Bros. Advisors LP | 4,909,810 9.990% | 0 (Unchanged) | Filing History |
| 2021-01-29 5:03 pm Purchase | 2021-01-23 | 13D | IGM Biosciences, Inc. IGMS | Baker Bros. Advisors LP | 3,157,784 12.400% | 513 (+0.02%) | Filing History |
| 2021-01-29 4:55 pm Purchase | 2021-01-25 | 13D | Zymeworks Inc. ZYME | Baker Bros. Advisors LP | 4,909,810 9.990% | 47,396 (+0.97%) | Filing History |
| 2021-01-29 4:48 pm Purchase | 2021-01-22 | 13D | Prelude Therapeutics Incorporated PRLD | Baker Bros. Advisors LP | 10,126,417 28.800% | 5,189 (+0.05%) | Filing History |
| 2021-01-29 4:38 pm Sale | 2020-12-31 | 13G | Idera Pharmaceuticals, Inc. IDRA | Baker Bros. Advisors LP | 546,037 12.100% | -6,446 (-1.17%) | Filing History |